Ixekizumab + Tirzepatide
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriatic Arthritis
Conditions
Psoriatic Arthritis, Obesity
Trial Timeline
Sep 24, 2024 → Apr 1, 2026
NCT ID
NCT06588296About Ixekizumab + Tirzepatide
Ixekizumab + Tirzepatide is a phase 3 stage product being developed by Eli Lilly for Psoriatic Arthritis. The current trial status is active. This product is registered under clinical trial identifier NCT06588296. Target conditions include Psoriatic Arthritis, Obesity.
What happened to similar drugs?
10 of 20 similar drugs in Psoriatic Arthritis were approved
Approved (10) Terminated (0) Active (10)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07443956 | Pre-clinical | Recruiting |
| NCT06588283 | Phase 3 | Active |
| NCT06588296 | Phase 3 | Active |
Competing Products
20 competing products in Psoriatic Arthritis